HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#151 / 200 Total
HUSA - Houston American Energy Corp - Stock Price Chart
TickerHUSA [AMEX]
CompanyHouston American Energy Corp
CountryUSA
IndustryOil & Gas E&P
Market Cap23.23MEPS (ttm)-7.95
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-6.94%
P/S45.55EPS next 5Y-
P/B2.72EPS Q/Q-4663.89%
Dividend-Sales Q/Q-30.70%
Insider Own0.00%Inst Own10.29%
Insider Trans-Inst Trans-
Short Float9.14%Earnings-
Analyst Recom-Target Price-
Avg Volume1.44M52W Range3.85 - 32.00
Jul-11-25 08:30AM Houston American Energy Secures $5 Million in Strategic Financing to Acquire Texas Gulf Coast Development Site (GlobeNewswire) +10.64%
08:30AM Houston American Energy Corp. Secures $100 Million Equity Line of Credit to Fuel Growth and Support Strategic Acquisitions (GlobeNewswire)
Jul-01-25 09:55PM Univest Securities, LLC Congratulates Client Houston American Energy Corp. on its Latest Acquisition of Abundia Global Impact Group, LLC (GlobeNewswire) +5.19% -7.54%
02:30PM Houston American Energy Corp. Appoints Matthew T. Henninger to Board of Directors (GlobeNewswire)
02:25PM Houston American Energy Acquires Abundia Global Impact Group, Creating a Publicly Traded Innovator in Low-Carbon Fuels (GlobeNewswire)
Jun-25-25 05:00PM Univest Securities, LLC Announces Closing of $1.2 Million Registered Direct Offering for its Client Houston American Energy Corp. (NYSE American: HUSA) (GlobeNewswire) +5.50%
Jun-24-25 09:15AM Houston American Energy Corp. Announces $1.2 Million Registered Direct Offering (GlobeNewswire) -30.80%
Jun-20-25 05:00PM Univest Securities, LLC Announces Closing of $2.37 Million Registered Direct Offering for its Client Houston American Energy Corp. (NYSE American: HUSA) (GlobeNewswire) -15.43% +25.27%
Jun-18-25 08:00AM Houston American Energy Corp. Announces $2.37 Million Registered Direct Offering (GlobeNewswire) -12.50%
Jun-13-25 03:43PM Houston American Energy Corp. Provides Response to Unusual Market Action (GlobeNewswire) +119.19%
GLTO - Galecto Inc - Stock Price Chart
TickerGLTO [NASD]
CompanyGalecto Inc
CountryUSA
IndustryBiotechnology
Market Cap4.67MEPS (ttm)-15.45
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y14.83%
P/S-EPS next 5Y-
P/B0.38EPS Q/Q62.06%
Dividend-Sales Q/Q-
Insider Own13.48%Inst Own3.24%
Insider Trans-0.64%Inst Trans0.39%
Short Float3.23%EarningsMay 08/a
Analyst Recom1.00Target Price10.00
Avg Volume43.23K52W Range2.01 - 16.07
May-08-25 04:30PM Galecto Reports First Quarter 2025 Operating and Financial Results (GlobeNewswire) +5.15%
Mar-19-25 04:45PM Galecto Reports Full-Year 2024 Financial Results (GlobeNewswire)
Feb-06-25 08:00AM Galecto to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-14-24 09:55AM Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-01-24 08:30AM Galecto Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-18-24 08:15AM Galecto price target raised to $10 from $9 at Oppenheimer (TipRanks) +5.79%
Oct-15-24 08:30AM Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler (GlobeNewswire)
Oct-07-24 08:45AM Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines (GlobeNewswire) -27.53%
Aug-28-24 09:00AM Galecto Announces Reverse Stock Split (GlobeNewswire) -6.59%
Aug-12-24 10:53PM GLTO Stock Earnings: Galecto Beats EPS for Q2 2024 (InvestorPlace) +6.26%
CAPS - Capstone Holding Corp - Stock Price Chart
TickerCAPS [NASD]
CompanyCapstone Holding Corp
CountryUSA
IndustryBuilding Materials
Market Cap8.36MEPS (ttm)-22.43
P/E-EPS this Y98.42%
Forward P/E-EPS next Y-
PEG-EPS past 5Y1.77%
P/S0.19EPS next 5Y-
P/B0.31EPS Q/Q96.37%
Dividend-Sales Q/Q-15.60%
Insider Own52.70%Inst Own0.23%
Insider Trans0.00%Inst Trans2.53%
Short Float2.53%EarningsMay 09
Analyst Recom1.00Target Price6.00
Avg Volume426.27K52W Range1.30 - 16.18
Jul-09-25 09:00AM Capstone Highlights Platform Strategy to Modernize Building Products Distribution (ACCESSWIRE) +8.82%
Jul-01-25 08:00AM Capstone Signs LOI to Acquire Southeast Stone Co. (ACCESSWIRE) -21.11%
Jun-30-25 08:00AM Capstone Answers Key Investor Questions with New FAQ (ACCESSWIRE) +7.78%
Jun-17-25 09:00AM Capstone Holding Corp. (NASDAQ:CAPS), Secures $1 Million Pangaea Stone Order in Expanding Territory (ACCESSWIRE)
May-16-25 08:00AM Capstone Reaffirms $100M Revenue Target for 2025, Accelerates M&A Strategy with Flexible Growth Capital (ACCESSWIRE) +47.59%
Apr-09-25 09:00AM Capstone Targets Growth in Southeast, Identifies Key Acquisition Candidates (ACCESSWIRE)
Apr-02-25 08:30AM Cautious Optimism for Building Products Distribution Rising as Sustained Demand for New Residential Construction Expected (GlobeNewswire)
Apr-01-25 09:00AM Capstone Targets $100M Run Rate Increases Q4 Revenue and Executes Strategic Brand Expansion (ACCESSWIRE)
Mar-25-25 08:46AM Why Capstone Holding (CAPS) Skyrocketed on Monday? (Insider Monkey) +5.42%
Mar-20-25 07:45AM Capstone Sees Minimal Effect from China Tariffs, Decrease in Container Prices Offsets Tariffs (ACCESSWIRE)
HOWL - Werewolf Therapeutics Inc - Stock Price Chart
TickerHOWL [NASD]
CompanyWerewolf Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap53.40MEPS (ttm)-1.64
P/E-EPS this Y-6.99%
Forward P/E-EPS next Y1.61%
PEG-EPS past 5Y-20.76%
P/S46.84EPS next 5Y-3.68%
P/B0.93EPS Q/Q-3.67%
Dividend-Sales Q/Q-100.00%
Insider Own26.20%Inst Own47.56%
Insider Trans4.70%Inst Trans-3.56%
Short Float4.00%EarningsMay 08/b
Analyst Recom1.00Target Price8.40
Avg Volume512.10K52W Range0.60 - 4.18
Jul-09-25 08:00AM Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit (GlobeNewswire)
Jun-12-25 08:00AM Werewolf Therapeutics to Participate in the BIO International Convention (GlobeNewswire)
May-29-25 12:00PM Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know (Zacks)
08:00AM Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 04:01PM HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 (GlobeNewswire) -5.26%
May-13-25 08:00AM Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit (GlobeNewswire)
May-08-25 07:00AM Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.54%
May-06-25 05:10PM Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-05-25 08:05AM Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting (GlobeNewswire)
08:00AM Werewolf Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
HIT - Health In Tech Inc - Stock Price Chart
TickerHIT [NASD]
CompanyHealth In Tech Inc
CountryUSA
IndustrySoftware - Application
Market Cap61.78MEPS (ttm)0.02
P/E58.55EPS this Y150.00%
Forward P/E9.42EPS next Y380.00%
PEG0.30EPS past 5Y-
P/S2.76EPS next 5Y192.40%
P/B4.36EPS Q/Q363.16%
Dividend-Sales Q/Q56.39%
Insider Own85.59%Inst Own1.56%
Insider Trans0.00%Inst Trans0.85%
Short Float1.03%EarningsMay 28
Analyst Recom1.00Target Price2.27
Avg Volume491.68K52W Range0.51 - 7.59
Jun-02-25 08:45AM Health In Tech Chief Growth Officer to Be Featured on "New to The Street" Interview at NYSE (PR Newswire)
May-20-25 04:30PM Health In Tech to Participate as Gold Sponsor at American Trust Investment Services National Conference 2025 (PR Newswire)
May-13-25 04:30PM Health In Tech to Participate in the "2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow" Virtual Conference Presented by Maxim Group LLC on Tuesday, June 3rd at 4:00 p.m. EDT (PR Newswire) +6.81% -20.11%
Apr-30-25 04:30PM Health In Tech Appoints Former U.S. Ambassador Edward McMullen to Advisory Board (PR Newswire)
Apr-28-25 07:00AM Health In Tech's CEO Tim Johnson Discusses Company in 2025, Revenue Growth, and Healthcare on 'The Street Reports Podcast' Listen Now! (PR Newswire) -6.82%
Apr-16-25 11:56AM Health In Tech, Inc. (HIT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
Apr-14-25 04:30PM Health In Tech Announces First Quarter 2025 Financial Results (PR Newswire)
Apr-10-25 04:30PM Health In Tech Announces Appointment of Sanjay Shrestha to Board of Directors (PR Newswire) +8.46%
Apr-08-25 04:30PM Health In Tech to Announce First Quarter 2025 Financial Results on April 14, 2025 (PR Newswire) +10.58%
Mar-25-25 04:30PM Health in Tech Expands Access to Virtual Care Through Collaboration with DialCare (PR Newswire) +20.31%
SONN - Sonnet BioTherapeutics Holdings Inc - Stock Price Chart
TickerSONN [NASD]
CompanySonnet BioTherapeutics Holdings Inc
CountryUSA
IndustryBiotechnology
Market Cap16.37MEPS (ttm)-12.83
P/E-EPS this Y69.52%
Forward P/E-EPS next Y-
PEG-EPS past 5Y85.27%
P/S16.37EPS next 5Y-
P/B24.38EPS Q/Q-240.61%
Dividend-Sales Q/Q-
Insider Own1.17%Inst Own5.09%
Insider Trans0.00%Inst Trans74.16%
Short Float1.31%EarningsMay 20
Analyst Recom1.00Target Price20.00
Avg Volume2.86M52W Range1.08 - 10.02
May-01-25 09:00AM Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit (GlobeNewswire)
Apr-16-25 09:10AM Sonnet Releases Virtual Investor 'What This Means' Segment (GlobeNewswire)
Apr-04-25 09:00AM Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose (GlobeNewswire)
Apr-01-25 04:15PM Sonnet Announces Release of Corporate Update Video (GlobeNewswire) -5.22%
07:30AM Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. (GlobeNewswire)
Mar-26-25 09:05AM Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas (GlobeNewswire)
Mar-19-25 08:50AM Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein (GlobeNewswire)
Mar-11-25 08:45AM Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Feb-26-25 09:00AM Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors (GlobeNewswire)
Feb-19-25 08:35AM Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates (GlobeNewswire)
DAVE - Dave Inc - Stock Price Chart
TickerDAVE [NASD, RUT]
CompanyDave Inc
CountryUSA
IndustrySoftware - Application
Market Cap2.70BEPS (ttm)3.63
P/E55.76EPS this Y50.50%
Forward P/E25.19EPS next Y27.56%
PEG-EPS past 5Y-
P/S7.09EPS next 5Y-
P/B13.50EPS Q/Q-24.27%
Dividend-Sales Q/Q46.65%
Insider Own27.99%Inst Own61.39%
Insider Trans-8.40%Inst Trans2.02%
Short Float9.73%EarningsMay 08/b
Analyst Recom1.00Target Price221.00
Avg Volume476.81K52W Range28.74 - 286.45
Jul-11-25 03:00PM Intuit & 2 Other Profitable Stocks to Buy for 2H25 (Zacks) -11.88%
Jul-09-25 11:37AM DAVE's ExtraCash Acts as Life Support for Underbanked Finances (Zacks) -6.52%
08:45AM AEVA Stock Is Skyrocketing - Is the Hype Really Justified? (Zacks)
Jul-03-25 11:13AM Microvast Soars 850% in a Year: Should Investors be Onboard Now? (Zacks)
Jul-01-25 08:50AM DAVE INC (DAVE) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-30-25 11:32AM NU vs. DAVE: Which Fintech Stock Should Investors Back Right Now? (Zacks) +7.52%
09:40AM Are Business Services Stocks Lagging Cap Gemini (CGEMY) This Year? (Zacks)
Jun-23-25 07:48AM 4 Stock Market Winners Now With Relative Price Strength (Zacks)
Jun-20-25 08:43AM Zacks.com featured highlights include Intuit, Dave and Centrus Energy (Zacks) +5.04%
Jun-17-25 03:00PM Intuit & 2 Other Strong Buy Profitable Stocks for Your Portfolio (Zacks) -5.73%
NNNN - Anbio Biotechnology - Stock Price Chart
TickerNNNN [NASD]
CompanyAnbio Biotechnology
CountryGermany
IndustryMedical Instruments & Supplies
Market Cap7.09BEPS (ttm)0.06
P/E812.87EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S800.91EPS next 5Y-
P/B117.02EPS Q/Q-267.38%
Dividend-Sales Q/Q-36.00%
Insider Own9.57%Inst Own0.15%
Insider Trans0.00%Inst Trans310.54%
Short Float0.54%Earnings-
Analyst Recom-Target Price-
Avg Volume95.14K52W Range5.18 - 52.62
Jul-09-25 10:31AM Here Is What You Need To Know Before Investing In Anbio Biotechnology (NNNN) (Insider Monkey) +14.50%
Jul-04-25 06:00AM The IPO market in 2025 is being driven by a clear theme bigger is better (Yahoo Finance)
May-15-25 01:05AM Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions (GlobeNewswire) +6.12%
Feb-20-25 09:50AM Anbio Biotechnology Announces Closing of Initial Public Offering (GlobeNewswire)
Feb-18-25 06:10PM Anbio Biotechnology Announces Pricing of Initial Public Offering (GlobeNewswire)
LTRN - Lantern Pharma Inc - Stock Price Chart
TickerLTRN [NASD]
CompanyLantern Pharma Inc
CountryUSA
IndustryBiotechnology
Market Cap39.69MEPS (ttm)-1.84
P/E-EPS this Y4.66%
Forward P/E-EPS next Y-6.52%
PEG-EPS past 5Y-37.87%
P/S-EPS next 5Y-2.53%
P/B2.37EPS Q/Q16.94%
Dividend-Sales Q/Q-
Insider Own24.31%Inst Own11.37%
Insider Trans-10.75%Inst Trans-15.29%
Short Float3.21%EarningsMay 15/b
Analyst Recom1.00Target Price25.00
Avg Volume126.05K52W Range2.55 - 6.12
Jun-16-25 08:30AM Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years (Business Wire)
May-29-25 11:21PM Lantern Pharma Inc. (LTRN)'s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models (Insider Monkey) +9.06%
08:30AM Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials (Business Wire)
May-15-25 08:45AM Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates (Business Wire)
May-12-25 09:00AM Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need (Business Wire)
08:31AM EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients (Benzinga)
May-08-25 08:30AM Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET (Business Wire) -11.06%
May-05-25 08:55AM Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC) (Business Wire)
08:31AM EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial (Benzinga)
Apr-01-25 09:01PM Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com) -6.50%
YIBO - Planet Image International Ltd - Stock Price Chart
TickerYIBO [NASD]
CompanyPlanet Image International Ltd
CountryChina
IndustryComputer Hardware
Market Cap84.59MEPS (ttm)0.13
P/E11.67EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-4.89%
P/S0.56EPS next 5Y-
P/B1.49EPS Q/Q-25.50%
Dividend-Sales Q/Q-4.54%
Insider Own96.70%Inst Own0.04%
Insider Trans0.00%Inst Trans3.51%
Short Float5.21%Earnings-
Analyst Recom-Target Price-
Avg Volume107.58K52W Range0.95 - 17.47
Sep-13-24 04:45PM Planet Image International Limited Reports the First Half of Fiscal Year 2024 Unaudited Financial Results (PR Newswire)
Jan-29-24 12:35PM Planet Image International Limited Announces Closing of $5 Million Initial Public Offering (PR Newswire)
Jan-24-24 09:44PM Planet Image International Limited Announces Pricing of Initial Public Offering (PR Newswire)
1⋯1011121314151617181920
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.